Capstone Wealth Management (Alabama)’s Neurocrine Biosciences NBIX Stock Holding History

Capstone Wealth Management (Alabama)’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$360K	Buy	+2,135	New	+$317K	0.17%	93

Other funds holding NBIX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PBBUPS

PKO BP Bankowy Universal Pension Society Warsaw, Poland $350M AUM 272.18% 1-Year Est. Return

Aware Super Sydney, Australia $7.06B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Capstone Wealth Management (Alabama)'s NBIX Position: Q2 2026 in Review

Capstone Wealth Management (Alabama) opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 2,135 shares worth $360K. The stake represents 0.17% of the portfolio and ranks #93 among its holdings.

260 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Capstone Wealth Management (Alabama) held 2,135 shares of Neurocrine Biosciences worth $360K as of Q2 2026.
Neurocrine Biosciences was a new Capstone Wealth Management (Alabama) position in Q2 2026.
Neurocrine Biosciences made up 0.17% of Capstone Wealth Management (Alabama)'s portfolio in Q2 2026, its #93 holding.
260 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Capstone Wealth Management (Alabama)'s 13F filing for Q2 2026, filed 23 Jul 2026.